Edition:
United States

Mirati Therapeutics Inc (MRTX.OQ)

MRTX.OQ on NASDAQ Stock Exchange Global Select Market

48.95USD
15 Jun 2018
Change (% chg)

$-0.45 (-0.91%)
Prev Close
$49.40
Open
$49.50
Day's High
$50.50
Day's Low
$48.15
Volume
181,182
Avg. Vol
120,222
52-wk High
$50.70
52-wk Low
$3.00

Chart for

About

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase... (more)

Overall

Beta: 2.01
Market Cap(Mil.): $1,555.43
Shares Outstanding(Mil.): 31.78
Dividend: --
Yield (%): --

Financials

  MRTX.OQ Industry Sector
P/E (TTM): -- 240.92 34.18
EPS (TTM): -2.57 -- --
ROI: -56.54 -5.87 13.17
ROE: -56.80 -7.71 15.15

BRIEF-Mirati Therapeutics Reports Q1 Loss Per Share $0.51

* MIRATI THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS

May 07 2018

BRIEF-Mirati Therapeutics Q4 Loss Per Share $0.67

* MIRATI THERAPEUTICS REPORTS FOURTH QUARTER AND FULL-YEAR 2017 FINANCIAL RESULTS

Mar 08 2018

BRIEF-Beigene And Mirati Therapeutics Announce Exclusive License Agreement For Sitravatinib In The Asia Pacific Region

* BEIGENE AND MIRATI THERAPEUTICS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT FOR SITRAVATINIB IN THE ASIA PACIFIC REGION

Jan 08 2018

Earnings vs. Estimates